Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Conditions
Interventions
enoblituzumab plus ipilimumab
Locations
10
United States
UCLA Hematology-Oncology Clinic
Los Angeles, California, United States
Yale University
New Haven, Connecticut, United States
Mount Sinai Medical Center
Miami Beach, Florida, United States
University of Chicago
Chicago, Illinois, United States
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
Washington University School of Medicine in St. Louis
St Louis, Missouri, United States
Start Date
March 26, 2015
Primary Completion Date
November 9, 2017
Completion Date
September 26, 2018
Last Updated
February 8, 2022
NCT02621021
NCT07177937
NCT05671510
NCT03050268
NCT05969860
NCT03340506
Lead Sponsor
MacroGenics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions